Focused on genetic diseases and cancers, this biopharmaceutical firm develops therapies targeting Mendelian disorders. Investors track BridgeBio for its pipeline of precision medicines and partnerships with larger pharma companies.
2 members of Congress have disclosed 6 trades in BridgeBio Pharma, Inc. (BBIO), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-19 | Gilbert Cisneros | buy | $1K – $15K |
| 2026-03-18 | Gilbert Cisneros | buy | $1K – $15K |
| 2026-03-03 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-09-22 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-08-08 | Gilbert Cisneros | buy | $1K – $15K |
| 2018-10-23 | JOHN K. DELANEY | buy | $15K – $50K |